// App-Quantinova.ai

5501 : Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.

Researchers

Presenter

  • Jonathan A. Ledermann

Principal Investigators

  • Philipp Harter

  • Charlie Gourley

  • Michael Friedlander

  • Ignace Vergote

  • Gordon J. S. Rustin

  • Clare L. Scott

  • Werner Meier

  • Ronnie Shapira-Frommer

  • Tamar Safra

  • Daniela E. Matei

  • Anitra Fielding

  • Stuart Spencer

  • Philip Rowe

  • Elizabeth S. Lowe

  • Ursula A. Matulonis

Medical Centers

  • Kings College London, London, United Kingdom

  • AGO & Kliniken Essen Mitte, Essen, Germany

  • Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom

  • UNSW Clinical School, Prince of Wales Hospital, Randwick, Australia

  • University of Leuven, KUL, Leuven, Belgium

  • Mount Vernon Hospital, Northwood, United Kingdom

  • Royal Melbourne Hospital, Parkville, Australia

  • Frauenklinik, Evangelisches Krankenhaus Duesseldorf, Duesseldorf, Germany

  • Chaim Sheba Medical Center, Tel Hashomer, Israel

  • Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel

  • Indiana University School of Medicine, Indianapolis, IN

  • AstraZeneca, Macclesfield, United Kingdom

  • AstraZeneca, Gaithersburg, MD

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • Germany

  • United Kingdom

  • Australia

  • United States

  • Israel

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Gynaecological cancer

Biomarkers

  • N/A

Drug/Treatment

  • Olaparib

Outcome

  • Unknown

Study Design

  • Placebo Control

Phase

  • II

Study Id's

  • NCT00753545

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved